Si-Bone (SIBN) Gains from Investment Securities (2017 - 2018)
Si-Bone (SIBN) posted Gains from Investment Securities of $145000.0 for Q4 2018, down 68.27% on a QoQ basis from $457000.0 in Q3 2018, and up 110.14% year-over-year from $69000.0 in Q4 2017.
Powered by 
Analysis
Si-Bone (SIBN) Gains from Investment Securities (2017 - 2018) Analysis & Trends
Si-Bone has reported Gains from Investment Securities for 2 years, with the latest figure at $145000.0 in Q4 2018.
- On a quarterly basis, Gains from Investment Securities rose 110.14% year-over-year to $145000.0 in Q4 2018; TTM through Sep 2019 was $145000.0, a 80.67% decrease from a year earlier, with the FY2018 full-year figure at $826000.0, up 597.59% from the prior year.
- Gains from Investment Securities was $145000.0 for Q4 2018 at Si-Bone, down from $457000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $457000.0 in Q3 2018, with the low at $69000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | Si-Bone | 818.82 Mn | 672.88 Mn | 44.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 145,000.00 |
| Sep 30, 2018 | 457,000.00 |
| Jun 30, 2018 | 145,000.00 |
| Mar 31, 2018 | 79,000.00 |
| Dec 31, 2017 | 69,000.00 |